Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × acalabrutinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15 Other hematologic neoplasm 8 Plasma cell 3 Thoracic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Docetaxel 203 Prednisone 149 enzalutamide 129 Gemcitabine 122 Radiotherapy 116 Sunitinib 112 Cisplatin 101 Leuprolide 98 pembrolizumab 95 Abiraterone Acetate 94 bicalutamide 87 Nivolumab 84 Goserelin 82 Sorafenib 80 Paclitaxel 79 Carboplatin 76 Everolimus 72 Bevacizumab 71 Magnetic Resonance Spectroscopy 64 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61 pazopanib 56 radium Ra 223 dichloride 49 Ipilimumab 49 Zoledronic Acid 47 Cyclophosphamide 43 Radiosurgery 42 Filgrastim 42 Surveys and Questionnaires 40 gallium 68 PSMA-11 39 aldesleukin 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351739 2019-09-10

KEYNOTE143

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡